Company Overview and News
Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Encompass Health (EHC - Free Report) or Chemed (CHE - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
The home health industry is poised for tremendous growth driven by the growing geriatric U.S. population, the prevalence of chronic illness, high cost of treatment at inpatient settings and increased use of home healthcare technologies.
AMED CHE EHC
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Encompass Health (EHC - Free Report) and Chemed (CHE - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
It has been about a month since the last earnings report for Chemed (CHE - Free Report) . Shares have lost about 0.8% in that time frame, underperforming the S&P 500.
Chemed Corporation (CHE - Free Report) has been gaining investor confidence on a consistently strong performance and upbeat results. Over the past six months, the company’s share price has outperformed its industry. The stock has rallied 22.3% compared with the industry’s 19% rise. Also, the company has outpaced the S&P 500’s 3.1% gain.
INGN CHE PDCO
Investors looking for stocks in the Medical - Outpatient and Home Healthcare sector might want to consider either Encompass Health (EHC - Free Report) or Chemed (CHE - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
Investors with an interest in Medical - Outpatient and Home Healthcare stocks have likely encountered both Encompass Health (EHC - Free Report) and Chemed (CHE - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
Haemonetics Corporation (HAE - Free Report) reported adjusted earnings per share (EPS) of 59 cents in the first quarter of fiscal 2019, a 78.9% surge year over year. The bottom line also surpassed the Zacks Consensus Estimate of 42 cents.
ALGN GD ZTO HAE ISRG CHE
CVS Health Corporation’s (CVS - Free Report) second-quarter 2018 adjusted earnings per share (EPS) of $1.69 surged 27.1% year over year and exceeded the Zacks Consensus Estimate of $1.61. The quarter’s adjusted EPS considered an additional adjustment of goodwill impairment charge related to the Long-term Care (LTC) business.
ALGN ISRG CHE CVS
2018-08-08 zacks - 1
BioScrip, Inc. (BIOS - Free Report) incurred net loss of 14 cents per share from continuing operations in the second quarter of 2018 compared with net loss of 26 cents a year ago. The quarterly loss was wider than the Zacks Consensus Estimate of a loss of 10 cents per share.
ALGN OAS BIOS ISRG CHE
Penumbra, Inc. (PEN - Free Report) reported second-quarter 2018 adjusted earnings per share (EPS) of 15 cents against adjusted loss of 5 cents in the year-ago quarter. Moreover, the bottom line was well above the Zacks Consensus Estimate of earnings of 3 cents per share.
ALGN ELY ICFI PEN ISRG CHE
Surmodics, Inc. (SRDX - Free Report) reported adjusted earnings of 27 cents per share in third-quarter fiscal 2018, up 200% year over year. The Zacks Consensus Estimate was pegged at a loss of 8 cents.
ABT ELY ICFI SRDX ISRG CHE ILMN ABT
Teleflex (TFX - Free Report) announced earnings per share (EPS) from continuing operations of $2.47 for the second quarter of 2018, up 21.1% year over year. Also, the bottom line surpassed the Zacks Consensus Estimate by 2.5%. This year-over-year rise in earnings was driven by an increase in sales and improved margins.
ALGN ODP TFX ISRG CHE AES
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to CHE / Chemed Corp. on message board site Silicon Investor.
as of ET